Medline (NASDAQ:MDLN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Medline (NASDAQ:MDLN) have received an average rating of “Moderate Buy” from the twenty-nine brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $50.5385.

Several equities analysts have recently issued reports on the company. Wells Fargo & Company boosted their target price on Medline from $42.00 to $47.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Robert W. Baird reduced their target price on Medline from $57.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 3rd. BMO Capital Markets boosted their target price on Medline from $45.00 to $54.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. JPMorgan Chase & Co. boosted their target price on Medline from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, March 10th. Finally, UBS Group boosted their target price on Medline from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, February 26th.

Medline Stock Performance

MDLN opened at $36.54 on Thursday. The company has a quick ratio of 2.51, a current ratio of 4.41 and a debt-to-equity ratio of 0.65. Medline has a 52-week low of $32.81 and a 52-week high of $50.88. The stock has a market capitalization of $48.00 billion and a PE ratio of 114.19. The company’s 50 day simple moving average is $41.06.

Medline (NASDAQ:MDLN) last posted its earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.04. The business had revenue of $7.35 billion for the quarter. The business’s revenue was up 10.7% compared to the same quarter last year. Research analysts forecast that Medline will post 1.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jessi L. Corcoran purchased 5,000 shares of Medline stock in a transaction that occurred on Friday, June 5th. The shares were bought at an average cost of $34.15 per share, with a total value of $170,750.00. Following the completion of the purchase, the insider directly owned 5,000 shares in the company, valued at approximately $170,750. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.81% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Medline

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sound Income Strategies LLC purchased a new stake in Medline in the fourth quarter worth $25,000. Entrust Financial LLC purchased a new stake in Medline in the fourth quarter worth $26,000. NBC Securities Inc. purchased a new stake in Medline in the fourth quarter worth $28,000. Whipplewood Advisors LLC purchased a new stake in Medline in the first quarter worth $30,000. Finally, Global Retirement Partners LLC purchased a new stake in Medline in the fourth quarter worth $31,000.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Recent insider buying is helping sentiment, with Principal Accounting Officer Jessi L. Corcoran purchasing 5,000 shares at $34.15, signaling confidence from management.
• Positive Sentiment: Investors appear to be digesting Medline’s recently completed debt refinancing and new term loan structure as a cleaner balance sheet setup that reduces near-term financing uncertainty.
• Positive Sentiment: The large secondary offering was sold by existing shareholders rather than Medline issuing new shares, which may ease concerns about direct company-level dilution.
• Neutral Sentiment: Medline’s presentation at the Goldman Sachs healthcare conference kept the stock in focus, but the provided details did not include a major new operating catalyst.
• Neutral Sentiment: Management’s recent investor and analyst attention may be reinforcing the view that the company remains fundamentally solid after its strong recent earnings report.
• Negative Sentiment: Fresh securities-fraud investigation headlines could pressure the shares by raising legal and disclosure-risk concerns, even though no wrongdoing has been established.
• Negative Sentiment: Some analyst commentary has turned more cautious, including a recent Barclays target cut to $45 from $50, citing margin pressure concerns.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.